Company

Pharvaris N.V.

Headquarters: Leiden, Netherlands

Employees: 17

CEO: Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA

FSX: 9EN +3.30%

Market Cap

€828.9 Million

EUR as of July 1, 2024

US$890.3 Million

Market Cap History

Pharvaris N.V. market capitalization over time

Evolution of Pharvaris N.V. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Pharvaris N.V.

Detailed Description

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Pharvaris N.V. has the following listings and related stock indices.


Stock: FSX: 9EN wb_incandescent

Details

Headquarters:

J.H. Oortweg 21

Leiden, 2333 CH

Netherlands

Phone: 31 71 203 6410